Pluronic (R) triblock copolymer-based nanoformulations for cancer therapy: A 10-year overview

• Type: Another Publication in an International Scientific Journal
• Date: 2023

Authors

de Castro, KC (Author) Other; Coco, JC (Author) Other; dos Santos, EM (Author) Other; Ataide, JA (Author) Other; Martinez, RM (Author) Other; do Nascimento, MHM (Author) Other; Prata, J (Author) Other; da Fonte, PRML (Author) Other; Severino, P (Author) Other; Mazzola, PG (Author) Other; Baby, AR (Author) Other; Souto, EB (Author) FFUP; de Araujo, DR (Author) Other; Lopes, AM (Author) Other

Journal

Title: Journal of Controlled Release

Vol. 353

Pages: 802-822

ISSN: 0168-3659

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 0 Citations

Scopus

Scientific classification

CORDIS: Health sciences

Other information

Authenticus ID: P-00X-N5F

DOI: 10.1016/j.jconrel.2022.12.017

Abstract (EN): This paper provides a review of the literature on the use of Pluronic (R) triblock copolymers for drug encapsulation over the last 10 years. A special focus is given to the progress of drug delivery systems (e.g., micelles, liposomes, micro/nanoemulsions, hydrogels and nanogels, and polymersomes and niosomes); the beneficial aspects of Pluronic (R) triblock copolymers as biological response modifiers and as pharmaceutical additives, adjuvants, and stabilizers, are also discussed. The advantages and limitations encountered in developing site-specific targeting approaches based on Pluronic-based nanostructures in cancer treatment are highlighted, in addition to inno-vative examples for improving tumor cytotoxicity while reducing side effects.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 21